Professor James N'Dow | People | The University of Aberdeen

Professor James N'Dow

Chair in Surgery (Clin)

About

Email Address: j.ndow@abdn.ac.uk
Telephone Number: +44 (0)1224 438133
Office Address: Academic Urology Unit 2nd Floor Health Sciences Building Foresterhill Aberdeen AB25 2ZD
School/Department: School of Medicine, Medical Sciences and Nutrition

Biography

James N’Dow is Director of the Academic Urology Unit since its establishment in 2001. His research activity spans across evidence synthesis, trials, guideline development, implementation science and the use of big data to complement traditional trial data. He has consistently secured significant funding for research totalling over £43 million over the past 20 years; including being the Coordinator of two large EU IMI funded big data for better outcomes projects. He is Coordinator of the €12M EU IMI funded 5 year project on prostate cancer big data (https://prostate-pioneer.eu/), a large European Multidisciplinary Consortium of 35 partners from 9 countries to harness the power of Big data to inform clinical practice recommendations. He recently successfully coordinated a second €21.3M EU IMI funded large consortium of 36 partners called OPTIMA researching three solid cancers (Prostate, Breast and Lung cancers).

He was Coordinating Editor of the Cochrane Incontinence Review Group and has a track record in delivering NIHR funded national trials in urology. He is co-lead for the recently funded British Association of Urological Surgeons TUF Trials Unit awarded to CHaRT. Appointed Chair of European Association of Urology Guideline Office Board in 2014. Under his leadership, the EAU Guidelines have become the most comprehensive and trusted urological surgical practice guidelines globally, endorsed by 75 countries.

Co-founder and MD of UCAN. UCAN has led 3 fundraising campaigns over the past 15 years, raising over £7 million in philanthropic contributions (cash and in-kind) galvanising the support of the local business community. UCAN funded the opening of the first Urological Cancer Care Centre in Scotland, brought the first robotics surgical system to Scotland as well as contributing £2,517,000 to University of Aberdeen for urological cancer related research. He is also Founder and trustee for Horizons Trust UK charitable trust.

Qualifications

MB ChB Medicine
1990 - University of Aberdeen
FRCS (Ed) Surgery
1994 - Royal College of Surgeons of Edinburgh
MD Medicine
1999 - University of Newcastle
With Commendation
FRCS (Urol) Urology
1999 - Royal College of Surgeons of Edinburgh

Memberships and Affiliations

Internal Memberships: University of Aberdeen (2001 onwards)

University of Newcastle (1994 – 2001)
External Memberships: Fellow, Royal College of Surgeons of Edinburgh

Fellow, Royal College of Surgeons of England

British Association of Urological Surgeons

Medical and Dental Defence Union

European Association of Urology

Association of Academic European Urologist

Research

Research Overview

About Urology Trials:

Urology (AUU) has a strong track record of delivering NIHR funded multicentre randomised trials in collaboration with other urologists across the UK as well as uro-gynaecologists and forms a significant proportion of CHaRT’s trial portfolio. Some examples of Urology trials are:

James N’Dow (AUU Director) and Graeme MacLennan (CHaRT Director) are co-Lead for the British Association of Urological Surgeons TUF Trials Unit 3 year award (starting 2021).

A unique strength has always been AUU’s willingness to support other clinical academic surgeons as aspiring trialists to develop and lead trials themselves thereby building capacity of senior academic surgeons as Chief Investigators. The BAUS TUF Trials Unit allows AUU and CHaRT to support the Urological Community to mentor and develop the next generation of Urological Surgeon trialists.

About PIONEER:
A €12M EU IMI funded 5 year project on prostate cancer big data (https://prostate-pioneer.eu/), a large European Multidisciplinary Consortium of 35 partners from 9 countries to encourage the global urological community to harness the power of real world (Big) data to inform clinical practice recommendations in the field of Prostate Cancer.

Nature Reviews Urology Publication – Introducing PIONEER https://rdcu.be/cqUmi

PIONEER presents a unique opportunity to contribute to critical patient focussed Pan-European Prostate Cancer research. PIONEER has prioritised 56 unanswered research questions using Delphi consensus methodology with all key stakeholders involved in the prioritisation exercise. Prostate Cancer patients from Grampian, across the UK and from the EU countries were involved.

The EAU Prostate Cancer Guideline panel and other prostate cancer Key Opinion Leaders were consulted to propose the most critical questions in the field of prostate cancer to be answered using big data. A two round Delphi survey including 73 healthcare professionals and 57 patients participated in round one followed by 49 healthcare professionals and 169 patients (including 53 English; 19 French; 31 German; 53 Italian; 13 Spanish) in round two, twelve additional questions were proposed during this first round. 56 questions were finally prioritised to be “critically important”.

Over the next 5 years, we expect to answer 10 prioritised research questions using federated analytics methodologies. To do this, PIONEER has had to map datasets to a common data model (OMOP) to allow reliable comparisons of outcomes across different datasets and countries (PIONEER has over 90 datasets in the pipeline for onboarding onto the PIONEER platform).

PIONEER is also exploring inclusion of hospital EHR data with Grampian (DaSH) being an early pilot centre. Researchers will only access pseudonymised data and no patient level data will be released from the DaSH environment. The results of this research will inform European Prostate cancer clinical practice guidelines.

About OPTIMA:
OPTIMA is a € 21.3 million European Commission Innovative Medicines Initiative funded research on patients with solid tumours leveraging the power of real world data analytics and artificial intelligence (AI). It is a five-year project, involving 36 partners across 13 countries. OPTIMA’s mission is to design, develop and deliver the first interoperable and GDPR-compliant European real-world oncology data and evidence generation platform. To achieve this ambitious goal OPTIMA will:

Establish a harmonised large scale real-world evidence data platform for prostate, breast and lung cancer with real-world date covering > 200 million people. The platform will be secure, sustainable and interoperable hosting datasets, data analysis tools, federated learning tools, AI algorithms, and electronic decision support tools.
Drive new knowledge generation through advanced analytics and AI-models. OPTIMA will identify and prioritise the main knowledge gaps in prostate, breast and lung cancer. Based on the key unanswered questions in each of the 3 cancer types, OPTIMA will develop specific AI-models to fill knowledge gaps and propose improved guideline recommendations.
Develop electronic shared decision support tools. These tools will be based on computer-interpretable guidelines developed by combining declarative AI and clinical care pathways developed from the leading clinical practice guidelines for prostate, breast and lung cancer. The electronic decision support tools will be interfaced with patient electronic health records (EHR).

OPTIMA aims at personalisation of treatment, encompassing the richness of available data by processing high-dimensional data across datasets and sources, and using deep learning to identify the decisive factors that enable personalised, real-time decisions for each individual patient based on the most accurate and complete weighing of available knowledge. If successful in its objectives OPTIMA will also inform policy on a European level when it comes to the clinical deployment of AI algorithms in healthcare.

As academic coordinator for both PIONEER and OPTIMA, there are unique opportunities to expand evidence generation to include incorporation of real world evidence into the evidence profiles underpinning clinical practice guidelines development. This would further cement the Academic Urology Unit and the EAU as leaders in the methodologies of Clinical Practice Guidelines development by incorporating real world data analytics and new evidence informed by AI models.

About Clinical Practice Guidelines and Implementation Science:
Whilst the development and global dissemination of evidence based guidelines was transformative for urological practice, it was clear that adherence to guideline recommendations was still suboptimal and there were potentially a myriad of reasons for non-adherence:

IMAGINE (IMpact Assessment of Guidelines Implementation and Education):
IMAGINE is a Pan-European National Urological Society Implementation Science Collaborative established to monitor clinical practice variation across over 40 European countries, to monitor baseline adherence to guideline recommendations and to identify determinants of non-adherence. IMAGINE will go on to develop knowledge transfer interventions geared to improve adherence. The first pilot has seen adherence data capture relating to treatment of over 6000 patients. To find out more on IMAGINE’s objectives, please see the following editorial and a recent publication.

Improving guideline adherence in urology 2021 - Accepted/In press European Urology Focus

MacLennan, S., Duncan, E., Skolarus, T. A., Roobol, M. J., Kasivisvanathan, V., Gallagher, K. M., Gandaglia, G., Sakalis, V., Smith, E. J., Plass, K., Ribal, M. J., N'Dow, J., Briganti, A.:

Research Areas

Applied Health Sciences

Supervising

View Research Area

Collaborations

Extensive collaborations across the world.

National – well connected with Urologists across the UK and strong links with the British Association of Urological Surgeons.

International – having spearheaded the engagement and endorsement of the European Urological clinical practice guidelines by National Urological Societies in 75 countries between 2014 – 2021, a strong network exists across all continents around the globe. As adjunct Secretary General of the EAU responsible for Education, I meet with representatives of all European National Urological Societies few times a year to discuss shared interests and collaborative opportunities.

PIONEER Partners:

1	STICHTING EUROPEAN UROLOGICAL FOUNDATION	EAU	Netherlands
2	LUNDS UNIVERSITET	LU	Sweden
3	UNIVERSITA VITA-SALUTE SAN RAFFAELE	USR	Italy
4	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM	Erasmus MC	Netherlands
5	UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF	UKE	Germany
6	TAMPEREEN KORKEAKOULUSAATIO SR	TAU	Finland
7	KING'S COLLEGE LONDON	KCL	United Kingdom
8	EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL	EORTC	Belgium
9	TTOPSTART BV	TTOP	Netherlands
10	INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD	ICHOM	United Kingdom
11	EUROPEAN CANCER PATIENT COALITION	ECPC	Belgium
12	ASSOCIATION EISBM	ASSOC EISBM	France
13	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE	Imperial	United Kingdom
14	THE HYVE BV	The Hyve	Netherlands
15	EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL	EAPM	Belgium
16	PINSENT MASONS LLP	PM	United Kingdom
18	WEIZMANN INSTITUTE OF SCIENCE	WEIZMANN	Israel
19	THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN	UoA	United Kingdom
20	TECHNISCHE UNIVERSITAET DRESDEN	TUD	Germany
21	FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.	Fraunhofer	Germany
22	GOETEBORGS UNIVERSITET	UGOT	Sweden
23	STICHTING RADBOUD UNIVERSITEIT	RUMC	Netherlands
24	IHE, INSTITUTET FOR HALSOOCH SJUKVARDSEKONOMI AKTIEBOLAG	IHE	Sweden
25	BAYER AKTIENGESELLSCHAFT	Bayer AG	Germany
26	SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT	SAN	France
28	ASTELLAS PHARMA EUROPE BV	ASTELLAS	Netherlands
29	NV SAS INSTITUTE SA	SAS	Belgium
30	JANSSEN PHARMACEUTICA NV	JANSSEN	Belgium
31	COVANCE LABORATORIES LTD	COVANCE	United Kingdom
32	ORION OYJ	ORION	Finland
33	IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED	IQVIA	United Kingdom
34	THE ECANCER GLOBAL FOUNDATION	eGF-eCancer	United Kingdom
35	JULIUS CLINICAL RESEARCH BV	Julius Clinical	Netherlands
36	ASTRAZENECA AB	AstraZeneca	Sweden
37	HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV	HZDR	Germany

OPTIMA Partners:

1. Stichting EAU Foundation for Urological Research (EAU) NL
2. Lund University (LU) SE
3. Erasmus Universitair Medisch Centrum Rotterdam (EMC) NL
4. Association EISBM (EISBM) FR
5. The University Court of the University of Aberdeen (UoA) UK
6. Tartu Ülikool (TU) EE
7. Universita Vita-Salute San Raffaele (UNISR) IT
8. Queen Mary University of London (QMUL) UK
9. CASUS, Helmholtz-Zentrum Dresden - Rossendorf (HZDR) DE
10. Helios Klinikum Emil von Behring (HC) DE
11. Uppsala University (UU) SE
12. Oxford University (UOXF) UK
13. University of Vienna (UNIVIE) AT
14. European Institute of Oncology (IEO) IT
15.Ludwig-Maximilians-University Munich (LMU) DE
16. University College London (UCL) UK
17. European Organisation for Research and Treatment of Cancer (EORTC) BE
18. Institut de Cancerologie de l’Ouest (ICO) FR
19. Maastricht University (MU) NL
20. Institut Universitari d’Investigacio en Atencio Primaria (IDIAPJGol) ES
21. European Respiratory Society (ERS) CH
22. German Cancer Society (DKG) DE
23. European Lung Foundation (ELF) UK
24. European Cancer Patient Coalition (ECPC) BE
25. ttopstart (TTOP) NL
26. GMV Soluciones Globales de Internet SAU (GMV) ES
27. Information Technology for Translational Medicine (ITTM) LU
28. SmartReporting GMBH (SR) DE
29. Owkin (OWK) FR
30. Arttic Innovation (ART) DE
31. YDEAL software PT
32. Pfizer UK
33. Bayer AG DE
34. Amgen CH
35. Roche CH
36. Abbvie US

Funding and Grants

2004 – 2009	NCCHTA	Conservative treatment for urinary incontinence in men after prostate surgery (MAPS Trial)	£1,252,961
2004 – 2007	BUPA Foundation	Prospective collaborative study of patients with intestinal segments transposed into the urinary tract following surgery for bladder cancer or benign end-stage bladder disease (OTIS Study)	£179,857
2005 – 2006	NCCHTA	Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement (BPE)	£108,410
2006 - 2009	NCCHTA	Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial of antibiotic and antiseptic impregnated urethral catheters.	£1,323,470
2007 - 2009	NCCHTA	Systematic review and economic modelling of the effectiveness and efficiency of non-surgical treatments of women with stress urinary incontinence (SUI)	£204,031
2010 – 2013	NIHR HTA	'Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker (nifedipine) and an alpha blocker (tamsulosin)' (SUSPEND)	£1,452,458
2010 – 2015	NIHR	Cochrane Incontinence Review Group Editorial Base Funding	£590,000
2012 – 2015	NIHR	Systematic review and economic modelling of ablative therapy for men with localised prostate cancer	£292,253
2012 – 2015	CRANES	Development of core outcomes for surgical management of localised prostate cancer to support decision-making by patients, clinicians and policy makers	£176,903
2013 – 2015	Macmillan Cancer Support	Cancer Survival, Work and Working Life: Developing a Patient Advice & Information System for Scotland	£106,000
2013 – 2016	Prostate Cancer UK	Extending the UCAN model of patient information and support to remote and rural communities	£229,134
2013 – 2016	NIHR HTAP	TISU Trial: A multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic retrieval, for ureteric stones	£1,426,755
2012 – 2017	NIHR HTAP	OPEN Trial: A multicentre randomised controlled trial of urethroplasty versus optical urethrotomy for recurrent bulbar urethral stricture disease	£1,324,614
2013 – 2016	NIHR HTAP	ANTIC Trial: A multicentre randomised controlled trial of antibiotic prophylaxis for clean intermittent self catheterisation	£1,821,671
2014 – 2020	NIHR HTAP	PHOTO Trial: A multicentre randomised controlled trial of Photodynamic guided treatment for bladder cancer	£2,380,539
2018 – 2023	NIHR HTAP	CATHETER II Trial: Randomised Controlled Trial CompAring THE Clinical And CosT-Effectiveness Of VaRious Washout Policies Versus No Washout Policy In Preventing Catheter Associated Complications In Adults Living With Long-Term Catheters	£2,270,000
2018 – 2023 2021 - 2026	European Commission Innovative Medicines Initiative European Commission Innovative Medicines Initiative	PIONEER: European Network of Excellence for Big Data in Prostate Cancer Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence	€12,000,000 €21, 300,000

Teaching

Non-course Teaching Responsibilities

Trainer of East of Scotland Urology Specialist Registrars.

Provide research training to medical students as part of the Aberdeen Summer Research Scholarship programme (ASRS).

PhD supervisor.

Trainer and mentor of young academic urological surgeons in evidence synthesis methodology and real world data analytics.

Responsible for Education portfolio of European Association of Urology that has a membership of 19,000 urological surgeons.

Publications

Update

Biography

Qualifications

Memberships and Affiliations

Research Overview

About Urology Trials:

Research Areas

Applied Health Sciences

Collaborations

Funding and Grants

Non-course Teaching Responsibilities

Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT

TISU: Extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic treatment, for ureteric stones: study protocol for a randomised controlled trial

Adherence to the European Association of Urology Guidelines: A National Survey among Italian Urologists

Care pathways for the management of localised and locally advanced prostate cancer:: Experience of the EAU guidelines office

How to resolve discrepancies when findings from randomized controlled trials and meta-analyses disagree?

Key steps in conducting systematic reviews for underpinning clinical practice guidelines:: Methodology of the European Association of Urology

What are core outcome sets, how should they be developed and why are they essential for urology?

Care pathways for the management of metastatic and castration-resistant prostate cancer in the era of novel therapeutic options:: Experience of the EAU guidelines office

Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology

Update on Genitourinary Pathology: From the Latest Morphological Novelties to Molecular Pathology and Genomics

A core outcome set for localised prostate cancer effectiveness trials

A core outcome set for localised prostate cancer effectiveness trials

Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better

Prostate Cancer Management in an Ageing Population

Reply to Philipp Dahm, Vikram Narayan, and Jae Hung Jung's Letter to the Editor re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. Eur Urol 2017;71:811-9

Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606-17

Changing Current Practice in Urology: Improving Guideline Development and Implementation Through Stakeholder Engagement

The SIMS trial: adjustable anchored single-incision mini-slings versus standard tension-free midurethral slings in the surgical management of female stress urinary incontinence. A study protocol for a pragmatic, multicentre, non-inferiority randomised controlled trial

Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology

Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree

Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease

Antibiotic treatment for intermittent bladder catheterisation with once daily prophylaxis (the AnTIC study): Study protocol for a randomised controlled trial

European Association of Urology (EAU) guidelines: do we care? Reflections from the EAU Impact Assessment of Guidelines Implementation and Education group

Endoscopic capacity in West Africa

Kurzdarstellung aktueller publikationen: Begünstigt eine muskelrelaxierende therapie den uretersteinabgang?

Open urethroplasty versus endoscopic urethrotomy - clarifying the management of men with recurrent urethral stricture (the OPEN trial): study protocol for a randomised controlled trial

Surgical management for localised penile cancer: [Cochrane Protocol]

Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)

Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial

Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation

Surgical management for localised penile cancer

A core outcome set for localised prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey

Significance of MUC1 in Bladder Cancer

The Effect of Dietary and Exercise Interventions on Body Weight in Prostate Cancer Patients: A Systematic Review

The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review

Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin): study protocol for a randomized controlled trial

Effectiveness of short-term antiseptic and antimicrobial-coated urethral catheters in reducing catheter-associated urinary tract infections:: Cochrane systematic review and meta-analysis

Communicating good care: A qualitative study of what people with urological cancer value in interactions with health care providers

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction

Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP)

Systematic Review of Adrenalectomy and Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma

Multicenter Prospective Randomized Study of Single-incision Mini-sling Vs Tension-free Vaginal Tape-obturator in Management of Female Stress Urinary Incontinence: A Minimum of 1-Year Follow-up

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction

Provision of cancer information as a "support for navigating the knowledge landscape": Findings from a critical interpretive literature synthesis

Authors' reply - Assessing catheter-associated urinary tract infection

Re: Huang et al.: Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy (urology 2012;80:1116-1120)

The effect of dietary and exercise interventions on body weight in men diagnosed with prostate cancer: A systematic review

Systematic review and meta-analysis of the clinical effectiveness of bipolar compared to monopolar transurethral resection of the prostate

Systematic review and meta-analysis of the clinical effectiveness of bipolar compared to monopolar transurethral resection of the prostate

Factors influencing women's decision to participate or not in a surgical randomised controlled trial for surgical treatment of female stress urinary incontinence

Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial

Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer

A multicentre prospective randomised study of single-incision mini-sling (Ajust ®) versus tension-free vaginal tape-obturator (TVT-O™) in the management of female stress urinary incontinence: pain profile and short-term outcomes

Prospective randomised controlled trial of transobturator tapes in management of urodynamic stress incontinence in women: 3-year outcomes from the Evaluation of Transobturator Tapes study

Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial)

Corrigendum to "systematic review of oncological outcomes following surgical management of localised renal cancer" [Eur Urol 2012;61:972-93]

Machine learning for improved pathological staging of prostate cancer: A performance comparison on a range of classifiers

Systematic review of oncological outcomes following surgical management of localised renal cancer

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction

Provision of a healthy weight maintenance programme for men treated for prostate cancer: a study of patients’ preferences

Enabling mutual helping?: Examining variable needs for facilitated peer support

Assessing risk of bias in non-randomised studies and incorporating GRADE: Initial experience with a new Cochrane ‘risk of bias’ tool under development

Re: N'Dow J, Washout policies in long-term indwelling urinary catheterization in adults: A short version cochrane review, neurourology and urodynamics 30: 1208-1212 (2011)

Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials

Defining a patient-reported outcome measure for urethral stricture surgery

The future of clinical practice guidelines in urology

Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials

Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials

Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines

Concepts of information provision in cancer care: a critical interpretive synthesis of literature